These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21062929)

  • 21. Steps and time to process clinical trials at the Cancer Therapy Evaluation Program.
    Dilts DM; Sandler AB; Cheng SK; Crites JS; Ferranti LB; Wu AY; Finnigan S; Friedman S; Mooney M; Abrams J
    J Clin Oncol; 2009 Apr; 27(11):1761-6. PubMed ID: 19255315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute: industry collaborations in new agent development.
    Ansher SS; Scharf R;
    Ann N Y Acad Sci; 2001 Dec; 949():333-40. PubMed ID: 11795372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials.
    Bennette CS; Ramsey SD; McDermott CL; Carlson JJ; Basu A; Veenstra DL
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26714555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Who's Eligible Anyway? Risk Modeling for Clinical Trial Accrual.
    Mileham KF; Kim ES
    Clin Cancer Res; 2016 Nov; 22(22):5397-5399. PubMed ID: 27601589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experience of the National Cancer Institute Community Cancer Centers Program on Community-Based Cancer Clinical Trials Activity.
    Hirsch BR; Locke SC; Abernethy AP
    J Oncol Pract; 2016 Apr; 12(4):e350-8. PubMed ID: 27026649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leveraging National Cancer Institute Programmatic Collaboration for Uterine Cervix Cancer Patient Accrual in Puerto Rico.
    Kunos CA; Massett HA; Galassi A; Walker JL; Good MJ; Díaz LB; McCaskill-Stevens W
    Front Oncol; 2018; 8():102. PubMed ID: 29692980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of state-mandated insurance coverage on accrual to community cancer clinical trials.
    Ellis SD; Carpenter WR; Minasian LM; Weiner BJ
    Contemp Clin Trials; 2012 Sep; 33(5):933-41. PubMed ID: 22683991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Community Clinical Oncology Program participation in the Breast Cancer Prevention Trial: factors affecting accrual.
    Klabunde C; Kaluzny A; Ford L
    Cancer Epidemiol Biomarkers Prev; 1995; 4(7):783-9. PubMed ID: 8672997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth in eligibility criteria content and failure to accrue among National Cancer Institute (NCI)-affiliated clinical trials.
    Peterson JS; Plana D; Bitterman DS; Johnson SB; Aerts HJWL; Kann BH
    Cancer Med; 2023 Feb; 12(4):4715-4724. PubMed ID: 36398619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations.
    Denicoff AM; McCaskill-Stevens W; Grubbs SS; Bruinooge SS; Comis RL; Devine P; Dilts DM; Duff ME; Ford JG; Joffe S; Schapira L; Weinfurt KP; Michaels M; Raghavan D; Richmond ES; Zon R; Albrecht TL; Bookman MA; Dowlati A; Enos RA; Fouad MN; Good M; Hicks WJ; Loehrer PJ; Lyss AP; Wolff SN; Wujcik DM; Meropol NJ
    J Oncol Pract; 2013 Nov; 9(6):267-76. PubMed ID: 24130252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assuring access to state-of-the-art care for U.S. minority populations: the first 2 years of the Minority-Based Community Clinical Oncology Program.
    Kaluzny A; Brawley O; Garson-Angert D; Shaw J; Godley P; Warnecke R; Ford L
    J Natl Cancer Inst; 1993 Dec; 85(23):1945-50. PubMed ID: 8230286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials.
    Lynce F; Blackburn MJ; Cai L; Wang H; Rubinstein L; Harris P; Isaacs C; Pohlmann PR
    Breast Cancer Res Treat; 2018 Feb; 168(1):35-41. PubMed ID: 29119354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Consideration of factors of low accrual and methods for setting appropriate accrual periods: Japan Clinical Oncology Group study.
    Sasaki K; Mizusawa J; Bando H; Nakamura K; Kataoka T; Katayama H; Fukuda H; Hara H
    Trials; 2024 Oct; 25(1):665. PubMed ID: 39375801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accrual to the Breast Cancer Prevention Trial by participating Community Clinical Oncology Programs: a panel data analysis.
    Klabunde CN; Kaluzny AD
    Breast Cancer Res Treat; 1995 Jul; 35(1):43-50. PubMed ID: 7612903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials.
    Paul K; Sathianathen N; Dahm P; Le C; Konety BR
    J Urol; 2019 Aug; 202(2):385-391. PubMed ID: 31074679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.
    Abrams JS; Mooney MM; Zwiebel JA; Korn EL; Friedman SH; Finnigan SR; Schettino PR; Denicoff AM; Kruhm MG; Montello M; Misra RR; Ansher SS; DiPiazza KJ; Souhan EM; Wickerham DL; Giantonio BJ; O'Donnell RT; Sullivan DM; Soto NI; Fleming GF; Prindiville SA; Petryshyn RA; Hautala JA; Grad O; Zuckerman BL; Meyer RM; Yao JC; Baker LA; Buckner JC; Hortobagyi GN; Doroshow JH
    J Natl Cancer Inst; 2013 Jul; 105(13):954-9. PubMed ID: 23776198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accrual Prediction Program: A web-based clinical trials tool for monitoring and predicting accrual for early-phase cancer studies.
    Liu J; Wick JA; Mudaranthakam DP; Jiang Y; Mayo MS; Gajewski BJ
    Clin Trials; 2019 Dec; 16(6):657-664. PubMed ID: 31451012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trials.
    Gadgeel SM; Ivy P; Chen W; Mauer J; Smith D; Lorusso P
    Clin Lung Cancer; 2011 Jul; 12(4):218-23. PubMed ID: 21726820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accrual and statistical power failure in published adjuvant phase III oncology trials: a comprehensive analysis from 2013 to 2023.
    Villacampa G; Dennett S; Mello E; Holton J; Lai X; Kilburn L; Bliss J; Rekowski J; Yap C
    ESMO Open; 2024 Jul; 9(7):103603. PubMed ID: 38925083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.